Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Fig. S1. Homing and engraftment kinetics of TCL1-tg tumor cells in PKC-β WT and null mice.
  • Fig. S2. PKC-β deficiency does not overtly alter hematopoiesis.
  • Fig. S3. PKC-β chimeras engraft with comparable efficiency irrespective of donor or recipient genotype.
  • Fig. S4. Monocytes confer CLL survival support but not PKC-β–dependent EMDR, in contrast to MSCs.
  • Fig. S5. PKC-β–mediated EMDR involves increased protein expression of BCL-XL.
  • Fig. S6. CLL signaling pathways regulated by stromal PKC-β correlate with clinical outcomes.
  • Fig. S7. Stromal lysosomes and lysosomal biogenesis regulator TFEB are central to PKC-β–mediated EMDR.
  • Fig. S8. PKC-β is dispensable for in vitro and in vivo mobilization of leukemia.
  • Fig. S9. In vivo cotargeting of PKC-β does not contribute to increased off-target cytotoxicity.
  • Fig. S10. Scheme illustrating PKC-β–dependent EMDR.
  • Fig. S11. Representative fluorescence-activated cell sorting (FACS) gating strategies.
  • Table S1. Patient characteristics.
  • Table S2. Key resources.
  • References (5662)

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Data file S1 (Microsoft Excel format). Top deregulated genes from CLL RNA-seq in Fig. 3C.
  • Data file S2 (Microsoft Excel format). Proteomic clusters from Fig. 5 (B and C).
  • Data file S3 (Microsoft Excel format). Individual data from experiments with n < 20 per group.